FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a compound representing 4-methylbenzene sulphonate 6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-N-{[5-(methylsulphonyl)pyridin-2-yl]methyl}-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide, and to its new crystalline form. The invention also refers to a method for preparing the above compound and to a pharmaceutical composition, for treating a disease or a condition wherein inhibition of neutrophilic elastase activity with the above compound and/or crystalline form is considered to be effective.
EFFECT: what is prepared is the new compound and its crystalline form which can find application in medicine for treating an inflammatory disease or condition, such as COPD (chronic obstructive pulmonary disease).
15 cl, 8 dwg, 10 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS CONTAINING 3-(2, 2-DIFLUOROBENZO[d][1, 3]DIOXOL-5-YL)CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDINE-2-YL)BENZOIC ACID, AND ADMINISTRATION THEREOF | 2011 |
|
RU2592368C2 |
| COMPOUND, CERTAIN NOVEL FORMS THEREOF, PHARMACEUTICAL COMPOSITIONS BASED THEREON AND METHODS OF PRODUCTION AND USE | 2010 |
|
RU2507203C1 |
| SUCCINATE 2-((4-(1-METHYL-4-(PYRIDIN-4-YL)-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE SALT | 2007 |
|
RU2430918C2 |
| SOLID FORMS OF SELECTIVE CDK4/6 INHIBITOR | 2014 |
|
RU2619944C2 |
| CRYSTALLINE FORM OF COMPOUND SUPPRESSING PROTEIN KINASE ACTIVITY AND THE USE THEREOF | 2017 |
|
RU2744264C2 |
| PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | 2016 |
|
RU2712187C2 |
| METHOD FOR OBTAINING MODULATORS OF CYSTIC FIBROUSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | 2010 |
|
RU2553989C2 |
| PHARMACEUTICALLY ACCEPTABLE SALTS OF 2-{4-[(3S)-PIPERIDIN-3-YL]PHENYL}-2H-INDAZOLE-7-CARBOXAMIDE | 2009 |
|
RU2495035C2 |
| INTERMEDIATE COMPOUNDS AND METHODS OF OBTAINING 4-(ACETYLAMINO)-3-[(4-CHLOROPHENYL)THIO]-2-METHYL-1H-INDOLE-1-OF ACETIC ACID | 2010 |
|
RU2551852C2 |
| INHIBITORS OF HIV REPLICATION | 2011 |
|
RU2564445C2 |
